Empagliflozin CV Benefit Unaffected by HF Burden: EMPA-REG Empagliflozin CV Benefit Unaffected by HF Burden: EMPA-REG

In a clinical-trial update, researchers look into empagliflozin effects on type 2 diabetes patients who have heart failure at study baseline, incident heart failure during the trial, or not at all.Heartwire from Medscape
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news